ODS EXAM - Random Notes/Complete
Questions and Answers
Total Mesorectal Excision (TME) - -TME Improves local recurrence rates and
the
corresponding survival by as much as 20%. Macroscopic pathologic
assessment of the completeness of the
mesorectum, scored as complete, partially complete, or incomplete,
accurately predicts both local recurrence and
distant metastasis.
- Which description(s) of involvement implies LVI is present?
A.Lymphovascular space invasion
B.Perineural invasion
C.Both (a) and (b)
D.Neither (a) nor (b) - -A. Lymphovascular space invasion
- Which statement(s) is true regarding the Macroscopic Evaluation of the
Mesorectum data item?
A.Leave this field blank when the primary site is other than rectum.
B.Neoadjuvant therapy alters the coding of this data item.
C.Both (a) and (b)
D.Neither (a) nor (b) - -A. Leave this field blank when the primary site is
other than rectum.
*Neoadjuvant therapy does NOT alter coding data
- Which statement(s) is true regarding the coding of primary site for breast?
A. Generally, code C501 (central breast) is preferred over codes C502 - C505
(a specified breast quadrant).
B. C501 is preferred over C508.
C. Both (a) and (b)
D. Neither (a) nor (b) - -B. C501 is preferred over C508.
*C502-C505 are preferred over C501
C500 is preferred over C508
C501 is preferred over C508
- Which of the following description(s) applies to a lung tumor coded to C349
[Lung, NOS] per Appendix C?
, A.Only description of the lung tumor location is "originates in the bronchus"
B.Only description of the lung tumor location is "infrahilar area of the lung"
C.Both (a) and (b)
D.Neither (a) nor (b) - -C. Both (a) and (b)
- Which primary site(s) is typically coded for a transitional/urothelial cell
carcinoma arising in the kidney?
A.C649 (kidney)
B.C659 (renal pelvis)
C.Both (a) and (b)
D.Neither (a) nor (b) - -B. C659 (renal pelvis)
*Transitional cell carcinoma rarely arises in the kidney C649. Transitional cell
carcinoma of the upper urinary system
usually arises in the renal pelvis C659. Pathology must confirm it originated
in kidney to code kidney.
- For SEER Program cases diagnosed 01/01/2023 and later, which site is still
considered a paired organ when coding the Laterality data item?
A. C444 (Skin of scalp and neck)
B. C340 (Main bronchus)
C. C300 (Nasal cavity)
D. None of the above - -A. C444 (Skin of scalp and neck)
- Which flag still applies to cases diagnosed 01/01/2023 and later?
A. CoC Accredited
B. Date of Birth
C. Date of Diagnosis
D. None of the above - -A. CoC Accredited
The CoC Accredited Flag, effective for cases diagnosed 01/01/2018, identifies
abstracts from CoC-accredited hospitals. Further, for those abstracts, the flag
will indicate analytic versus non-analytic status. This flag still applies for
cases diagnosed 01/01/2023 and later.
*Data items deleted for cases diagnosed 01/01/2023 and later include:
Section III: Demographic Information: Date of Birth Flag
Section IV: Description of this Neoplasm: Date of Diagnosis Flag
Section VII: First Course of Therapy: All date treatment related flags for each
modality
Section VIII: Follow-Up Information: All follow-up related date flags
Questions and Answers
Total Mesorectal Excision (TME) - -TME Improves local recurrence rates and
the
corresponding survival by as much as 20%. Macroscopic pathologic
assessment of the completeness of the
mesorectum, scored as complete, partially complete, or incomplete,
accurately predicts both local recurrence and
distant metastasis.
- Which description(s) of involvement implies LVI is present?
A.Lymphovascular space invasion
B.Perineural invasion
C.Both (a) and (b)
D.Neither (a) nor (b) - -A. Lymphovascular space invasion
- Which statement(s) is true regarding the Macroscopic Evaluation of the
Mesorectum data item?
A.Leave this field blank when the primary site is other than rectum.
B.Neoadjuvant therapy alters the coding of this data item.
C.Both (a) and (b)
D.Neither (a) nor (b) - -A. Leave this field blank when the primary site is
other than rectum.
*Neoadjuvant therapy does NOT alter coding data
- Which statement(s) is true regarding the coding of primary site for breast?
A. Generally, code C501 (central breast) is preferred over codes C502 - C505
(a specified breast quadrant).
B. C501 is preferred over C508.
C. Both (a) and (b)
D. Neither (a) nor (b) - -B. C501 is preferred over C508.
*C502-C505 are preferred over C501
C500 is preferred over C508
C501 is preferred over C508
- Which of the following description(s) applies to a lung tumor coded to C349
[Lung, NOS] per Appendix C?
, A.Only description of the lung tumor location is "originates in the bronchus"
B.Only description of the lung tumor location is "infrahilar area of the lung"
C.Both (a) and (b)
D.Neither (a) nor (b) - -C. Both (a) and (b)
- Which primary site(s) is typically coded for a transitional/urothelial cell
carcinoma arising in the kidney?
A.C649 (kidney)
B.C659 (renal pelvis)
C.Both (a) and (b)
D.Neither (a) nor (b) - -B. C659 (renal pelvis)
*Transitional cell carcinoma rarely arises in the kidney C649. Transitional cell
carcinoma of the upper urinary system
usually arises in the renal pelvis C659. Pathology must confirm it originated
in kidney to code kidney.
- For SEER Program cases diagnosed 01/01/2023 and later, which site is still
considered a paired organ when coding the Laterality data item?
A. C444 (Skin of scalp and neck)
B. C340 (Main bronchus)
C. C300 (Nasal cavity)
D. None of the above - -A. C444 (Skin of scalp and neck)
- Which flag still applies to cases diagnosed 01/01/2023 and later?
A. CoC Accredited
B. Date of Birth
C. Date of Diagnosis
D. None of the above - -A. CoC Accredited
The CoC Accredited Flag, effective for cases diagnosed 01/01/2018, identifies
abstracts from CoC-accredited hospitals. Further, for those abstracts, the flag
will indicate analytic versus non-analytic status. This flag still applies for
cases diagnosed 01/01/2023 and later.
*Data items deleted for cases diagnosed 01/01/2023 and later include:
Section III: Demographic Information: Date of Birth Flag
Section IV: Description of this Neoplasm: Date of Diagnosis Flag
Section VII: First Course of Therapy: All date treatment related flags for each
modality
Section VIII: Follow-Up Information: All follow-up related date flags
